Residency · Residency · Obstetrics Gynecology

First-Trimester Pregnancy Loss Management

Introduction

First-trimester pregnancy loss, defined as a nonviable intrauterine pregnancy before 13 weeks of gestation, occurs in approximately 10 to 15% of clinically recognized pregnancies. The true incidence including preclinical losses may exceed 50%. Accurate diagnosis, compassionate counseling, and evidence-based management options including expectant, medical, and surgical approaches are core competencies for the obstetrician-gynecologist.

Definitions and Classification

Early pregnancy loss (previously termed missed abortion) refers to embryonic or fetal demise before 13 weeks without spontaneous expulsion. Incomplete abortion describes partial expulsion of products of conception with continued bleeding and an open cervical os. Complete abortion is full expulsion of all products of conception with a closed cervix and resolving symptoms. Threatened abortion is vaginal bleeding with a closed cervix and a viable intrauterine pregnancy. Inevitable abortion involves bleeding with cervical dilation but no passage of tissue. An anembryonic pregnancy (blighted ovum) is a gestational sac without identifiable embryonic structures. Recurrent pregnancy loss is defined by the ASRM as two or more failed clinical pregnancies.

Diagnosis

Ultrasound Criteria

Definitive diagnosis of nonviability, per the ACOG and Society of Radiologists in Ultrasound consensus criteria, requires a crown-rump length of 7 mm or greater with no cardiac activity, or a mean sac diameter of 25 mm or greater with no embryo visible. Findings that are suspicious but not diagnostic include a CRL less than 7 mm without cardiac activity, a mean sac diameter of 16 to 24 mm without an embryo, absence of an embryo with heartbeat 2 or more weeks after a scan showing a gestational sac without a yolk sac, or 11 or more days after a scan showing a gestational sac with a yolk sac. When there is any doubt, the ultrasound should be repeated in 7 to 14 days to confirm the diagnosis before any intervention.

Biochemical Markers

In viable early pregnancies, serial hCG rises by at least 53% every 48 hours, which represents the slowest normal rise. A decline or plateau suggests nonviability. The discriminatory zone is the hCG level above which an intrauterine pregnancy should be visible on transvaginal ultrasound, typically 1,500 to 3,500 mIU/mL. An empty uterus above this level raises concern for ectopic pregnancy. A single progesterone level below 5 ng/mL is strongly associated with a nonviable pregnancy, while a level above 20 ng/mL suggests viability.

<image>Transvaginal ultrasound images showing diagnostic criteria for first-trimester pregnancy loss: anembryonic pregnancy with mean sac diameter greater than 25 mm and no embryo, and embryonic demise with crown-rump length greater than 7 mm and absent cardiac activity</image>

Management Options

Expectant Management

Expectant management allows spontaneous expulsion of products of conception without intervention. The success rate is 80% within 8 weeks for incomplete abortion, 50 to 75% for embryonic demise over 2 to 6 weeks, and lower for anembryonic pregnancy. Appropriate patients are hemodynamically stable, have no signs of infection, have reliable follow-up, and prefer to avoid medication or surgery. Monitoring includes serial hCG levels, clinical follow-up, and ultrasound to confirm complete expulsion. Intervention is offered if expulsion is incomplete after the patient's defined waiting period. The advantage is avoiding medication side effects and procedural risks while allowing the natural process.

Medical Management

The most effective medical regimen is mifepristone 200 mg orally followed 24 hours later by misoprostol 800 mcg vaginally, achieving complete expulsion in 84 to 91% of cases by day 8. A misoprostol-only regimen of 800 mcg vaginally or sublingually, with a repeat dose in 24 to 48 hours if incomplete, has a success rate of 71 to 84%. Mifepristone pretreatment significantly improves efficacy, with a number needed to treat of 5 to prevent one surgical intervention. Pain management consists of NSAIDs (ibuprofen 600 to 800 mg every 6 to 8 hours) with opioid analgesics for breakthrough pain and anticipatory counseling about expected cramping and bleeding. The expected course includes heavy bleeding and cramping within 1 to 4 hours of misoprostol, passage of tissue within 4 to 8 hours, and bleeding that may continue for 1 to 2 weeks. Follow-up confirms completion by ultrasound (endometrial thickness less than 30 mm) or serum hCG decline at 7 to 14 days.

Surgical Management

Uterine aspiration using manual vacuum aspiration (MVA) or electric vacuum aspiration (EVA) is the definitive treatment, with a success rate exceeding 99%. Indications include patient preference, hemodynamic instability, signs of infection, failed medical or expectant management, and the desire for tissue for genetic analysis. Cervical preparation with misoprostol 400 mcg sublingual 1 to 3 hours prior or osmotic dilators may be used. A paracervical block with 1% lidocaine provides anesthesia. Suction aspiration is performed with an appropriate-sized cannula, typically 7 to 12 mm. Office-based MVA is safe and cost-effective for gestations up to 12 weeks. Complications are uncommon and include uterine perforation (less than 1%), cervical laceration, retained tissue, infection, and Asherman syndrome (rare).

<image>Illustration of manual vacuum aspiration technique for first-trimester pregnancy loss showing the syringe aspirator connected to a flexible cannula inserted through the dilated cervix, with labeled anatomy including uterine cavity, products of conception, and direction of suction</image>

Rh Status and Anti-D Immunoglobulin

Rh testing is recommended for all patients with pregnancy loss. Anti-D immunoglobulin (RhoGAM) should be administered to Rh-negative, unsensitized women: 50 mcg (MICRhoGAM) for losses before 12 weeks or 300 mcg for losses at 12 weeks or later. It should be given within 72 hours of the event, whether that is bleeding, passage of tissue, or a surgical procedure.

Emotional Support and Counseling

Pregnancy loss is a significant event, and the grief response should be acknowledged. Emotions should be validated, and screening for complicated grief, anxiety, and depression is important. The risk of subsequent loss after one loss is approximately 15 to 20%, similar to baseline. After two losses, the risk is 25 to 30%, and after three losses, 30 to 40%. Evaluation for recurrent pregnancy loss is recommended after two or more losses and includes karyotype of both partners, antiphospholipid antibody testing, uterine cavity evaluation, TSH, and hemoglobin A1c. There is no evidence supporting a delay in conception after early pregnancy loss; patients may conceive when they feel emotionally and physically ready.

Tissue Analysis

Aspirated tissue should be sent for histopathologic confirmation to verify intrauterine pregnancy and exclude gestational trophoblastic disease. Genetic analysis by karyotype or chromosomal microarray on products of conception can identify aneuploidy, which is present in 50 to 60% of sporadic losses. This is particularly useful in recurrent pregnancy loss evaluation. Gross examination involves floating tissue in saline, where chorionic villi appear as branching frond-like structures.

Clinical Pearls

Strict ultrasound criteria should be used for diagnosing nonviability. When uncertain, imaging should be repeated in 7 to 14 days rather than intervening prematurely.

Mifepristone pretreatment before misoprostol significantly improves success rates for medical management and should be standard of care.

All three management options -- expectant, medical, and surgical -- are safe and acceptable. Patient preference should guide the decision.

Office-based MVA is safe, effective, and cost-efficient. All OB-GYN residents should be proficient in this procedure.

Antiphospholipid syndrome and other treatable causes should be screened for after two or more pregnancy losses.

References

1. ACOG Practice Bulletin No. 200. Early Pregnancy Loss. Obstet Gynecol. 2018;132(5):e197-e207.
2. Schreiber CA, Creinin MD, Atrio J, et al. Mifepristone pretreatment for the medical management of early pregnancy loss. N Engl J Med. 2018;378(23):2161-2170.
3. Doubilet PM, Benson CB, Bourne T, et al. Diagnostic criteria for nonviable pregnancy early in the first trimester. N Engl J Med. 2013;369(15):1443-1451.
4. ASRM Practice Committee. Evaluation and treatment of recurrent pregnancy loss: a committee opinion. Fertil Steril. 2012;98(5):1103-1111.

Read this lecture as Markdown